Summary
Agilent Technologies, Inc. has announced a significant change in its reporting structure, moving its Cell Analysis Division into its Diagnostics and Genomics Group, effective with its first quarter fiscal 2024 results. This strategic realignment is intended to better align operations and potentially enhance reporting clarity for investors. The company plans to provide three years of historical financial data adjusted for this new structure in January 2024, facilitating a more accurate comparison of past and future performance across these segments.
Key Highlights
- 1Agilent Technologies is reorganizing its business segments, integrating the Cell Analysis Division into the Diagnostics and Genomics Group.
- 2This new reporting structure will be effective starting with the first quarter of fiscal year 2024.
- 3The company will provide three years of historical financial statements reflecting the new segments to ensure comparability.
- 4This information is being furnished and not deemed filed under Section 18 of the Securities Exchange Act.
- 5A press release dated December 20, 2023, details this change.
Frequently Asked Questions
Agilent Technologies is moving its Cell Analysis Division into its Diagnostics and Genomics Group. This change will affect how the company reports its financial results.
The new reporting structure will be implemented starting with Agilent's first quarter of fiscal year 2024.
Yes, Agilent plans to release three years of historical financial statements reflecting the new business segments in January 2024 to help investors compare information consistently.
No, the information provided in Item 8.01 and Exhibit 99.1 is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not carry the same legal liabilities as a formally filed document.